Cyrus Biotechnology Chief Science Officer Yifan Song to Speak at BAGIM – Boston Area Group for Informatics and Modeling
SEATTLE, WA March 11, 2019 — Cyrus Biotechnology, Inc., a Seattle-based biotech software company commercializing the advanced protein design platform Rosetta announced today that Dr Yifan Song, Cyrus Bio Chief Scientific Officer, will speak at an upcoming meeting of the Boston Area Group for Informatics and Modeling (BAGIM).
Topic: Got Structure? State-of-the-art protein structure prediction with homology modeling
Date:
Thursday, March 14th,
2019
Time: 6:00 PM EDT
Venue: Shire – 125
Binney St, Cambridge, MA 02142
Event
on Meetup:
https://www.meetup.com/Boston-Area-Group-for-Informatics-and-Modeling/events/259399520/
Abstract:
Most
computational methods that can be applied during drug discovery
require a protein structure. Ideally, such structures are derived
from experimental approaches such as X-ray, EM or NMR. However,
frequently, an experimental structure of the specific protein of
interest is not available. In such a case we turn to homology
modeling.
The state-of-the-art for homology model
prediction has progressed tremendously over the past two decades.
Whereas useful HM models were initially only available in cases where
a high-similarity homolog was available in the PDB, it is now often
possible to predict such models even when the best homologs have only
15-25% similarity to the sequence whose structure is being predicted.
The dramatic improvement in what is possible with HM is due to
several factors, including: adoption of methods that can identify
suitable low similarity templates on the basis of Markov Models,
familial and other deep analysis of sequence space; the ability to
incorporate multiple low-similarity templates to broadly span a
target sequence; powerful approaches to model building that can
handle missing structure due to lack of template, insertions and
deletions; and the availability of massive compute power through
processor clusters and parallelization. In many cases, the HM models
that can be generated are so good—not only in terms of backbone
trace, but also in such fine details as hydrogen bonding network,
salt bridges, disulphide bonds, etc.—that they are suitable for
downstream modeling methods.
We will present the history
of HM approaches, culminating in a description of the
state-of-the-art Rosetta HM workflow.
For
more information on Cyrus Bench, click here.
About
BAGIM (Boston Area Group for Informatics and Modeling)
BAGIM
is an active community of Boston area scientists bringing together
people from diverse fields of modeling and informatics to impact life
and health sciences. BAGIM strives to create a forum for great
scientific discussions covering a wide range of topics including data
management, visualization, computational chemistry, drug discovery,
protein structure, molecular modeling, structure-based drug design,
data mining, software tools, and the sharing of goals and
experiences. Our community is made up of participants from academia,
government, and/or industry whose goal is to engage in the discussion
of science involving a synthesis of theory and technology.
Discussions sponsored by BAGIM are targeted to the needs and
interests of informatics scientists, computational chemists,
medicinal chemists, and statisticians. BAGIM also provides
opportunities for networking within these disciplines as well as an
arena for the dissemination of information of specific interest to
the membership.
http://bagim.org
About
Cyrus
Cyrus
Biotechnology, Inc. is a privately-held biotechnology software
company offering Cyrus Bench®, a SaaS platform for protein
engineering to accelerate discovery of biologics and small molecules
for the Biotechnology, Pharmaceutical, Chemical, Consumer Products
and Synthetic Biology industries. Cyrus Bench® is based on the
Rosetta software from Prof. David Baker’s laboratory at the
University of Washington, the most powerful protein engineering
software available. Cyrus customers include 10 of the top 20 Global
Pharmaceutical firms and is financed by leading investors in both
Technology and Biotechnology, including Trinity Ventures, Orbimed,
Springrock Ventures, Alexandria Venture Investments, and W
Fund.
https://www.cyrusbio.com/
Cyrus Contact – Lucas Nivon
lucas@cyrusbio.com
206-258-6561